Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response

• US 8,709,397 B2
• Filed: 07/30/2012
• Issued: 04/29/2014
• Est. Priority Date: 06/24/2004
• Status: Active Grant

• Current Assignee: New York University
• Original Assignee: New York University
• Inventors: Mohr, Ian, Mulvey, Matthew
• Primary Examiner(s): Popa, Ileana
• Application Number:
  US13/561,823
• Publication Number:
  US 20130034586A1
• Time in Patent Office: 638 Days
• Field of Search: None
• US Class Current: 424/93.2
• CPC Class Codes: A61K 2039/5254 avirulent or attenuated
• CPC Class Codes: A61K 2039/5256 expressing foreign proteins
• CPC Class Codes: A61K 35/763 Herpes virus
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: C12N 15/86 Viral vectors
• CPC Class Codes: C12N 2710/16632 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
• CPC Class Codes: C12N 2710/16643 viral genome or elements thereof as genetic vector
• CPC Class Codes: C12N 2710/16661 Methods of inactivation or attenuation
• CPC Class Codes: C12N 2710/16662 by genetic engineering
• CPC Class Codes: C12N 7/00 Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00

Abstract

The present invention relates to an avirulent, oncolytic herpes simplex virus modified from a wild-type herpes simplex virus so that both γ₁34.5 genes of the virus have been deleted and each replaced with an interferon-resistance gene that is expressed as an immediate-early gene. The present invention also relates to a pharmaceutical composition that includes the modified herpes simplex virus of the present invention and a pharmaceutically acceptable vehicle for in situ administration to tumor cells. Also provided in the present invention are methods for killing tumor cells in a subject and for immunizing a subject against an infectious disease, cancer, or an autoimmune disease that involve administering to a subject the modified avirulent, oncolytic herpes simplex virus of the present invention.

Claims

1. A vaccine comprising:

(a) a modified herpes simplex virus (HSV), and

(b) a pharmaceutically acceptable vehicle for in situ administration to the subject,

wherein the modified HSV has an intact U_s12 gene and an endogenous U_s11 gene expressed as a late gene, and is modified from a wild-type HSV with both γ

₁34.5 genes of the virus being deleted and U_s11 genes that are expressed as intermediate early (IE) genes being inserted in the γ

₁34.5 gene locus in place of both γ

₁34.5 genes.

2. The vaccine of claim 1, wherein the modified HSV is avirulent.

3. The vaccine of claim 1, wherein the U_s11 genes are under control of an HSV IE promoter.

4. The vaccine of claim 1, wherein the promoter is an α

27 IE promoter.

5. The vaccine of claim 1, wherein the modified HSV further comprises an ICP 6-inactivating mutation.

6. The vaccine of claim 1, wherein the wild-type HSV is a herpes simplex virus type 1 (HSV-1).

7. The vaccine of claim 6, wherein the HSV-1 is a strain selected from the group consisting of HSV-1 strain 17, strain KOS, strain F, strain Patton and any clinical isolate thereof.

8. The vaccine of claim 1, wherein the wild-type HSV is a herpes simplex virus type 2 (HSV-2).

9. The vaccine of claim 8, wherein the HSV-2 is a strain selected from the group consisting of HSV-2 strain G, strain HG52 and any clinical isolate thereof.

10. The vaccine of claim 1, which is administered by injection, infusion, instillation or inhalation.

11. The vaccine of claim 1, which is suitable for immunizing a mammal.

12. The vaccine of claim 11, wherein the mammal is a human.